There is an ongoing phase 1 study evaluating GPC3/CD3 bsAb ERY974 in combination with atezolizumab and bevacizumab in patients with locally advanced or metastatic HCC [106]. The gene discussed is GPC3; the disease is hepatocellular carcinoma.